Results 231 to 240 of about 188,098 (289)
A Snail Galactosed Glycosaminoglycan Inhibits Thrombosis without Affecting Hemostasis via Disrupting FIXa-FVIIIa Complex Generation. [PDF]
ACS Cent SciLin L +13 more
europepmc +1 more source
Giant cellulitis‐like Sweet's syndrome induced by gilteritinib
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández +5 more
wiley +1 more source
Management of patients with protein s deficiency: focus on clinical course and direct oral anticoagulants. [PDF]
Thromb JNicola A +14 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy, 2000
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire +3 more sources
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire +3 more sources
Heparin and low-molecular-weight heparin
Thrombosis and Haemostasis, 2008SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration.
Elaine, Gray +2 more
openaire +2 more sources
Current Opinion in Cardiology, 1994
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire +2 more sources
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire +2 more sources
Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides
Clinics in Geriatric Medicine, 2006Elderly patients require special consideration when administered anticoagulants because of age-related alterations in renal function, protein binding, and increased bleeding risk. Unfractionated heparin can be used in most patients but difficulties with dosing and monitoring often lead to inadequate anticoagulation.
Danya L, Dinwoodey, Jack E, Ansell
openaire +2 more sources